Ascletis Pharma Inc

Company Profile

• Business description

  Ascletis Pharma Inc is an investment holding company. The company is a fully integrated biotechnology company focused on the development and commercialization of potential therapeutics to treat metabolic diseases. Along with its subsidiaries, it is engaged in the research, development, production, marketing, and sale of pharmaceutical products. The company uses its Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP) technologies and Peptide Oral Transport ENhancement Technology (POTENT) to develop multiple drug candidates in-house, including both small molecules and peptides. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.

• Contact

  No. 248 Queen’s Road East
  40th Floor, Dah Sing Financial Centre
  Wanchai
  Hong Kong311200
  HKG

  https://www.ascletis.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2026

  Employees

  202